Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 6/20 | 0.58 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.48 |
| ▸ | CCKBR | P32239 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392374 | 0.89 | KCNN4 (0.69) | KCNN4KCNA3NR1I2ADORA3TBXA2R | |
| SCHEMBL2403558 | 0.86 | KCNN4 (0.58) | KCNN4KCNA3NR1I2ADORA3TBXA2R | |
| SCHEMBL1750941 | 0.83 | KCNN4 (0.58) | KCNN4KCNA3NR1I2ADORA3TBXA2R | |
| SCHEMBL2361042 | 0.83 | KCNN4 (0.67) | KCNN4KCNA3NR1I2ADORA3TBXA2R | |
| SCHEMBL20772229 | 0.83 | KCNN4 (0.58) | KCNN4KCNA3NR1I2ADORA3TBXA2R | |
| SCHEMBL2338372 | 0.80 | KCNN4 (0.72) | KCNN4KCNA3NR1I2ADORA3TBXA2R | |
| SCHEMBL11199996 | 0.79 | KCNN4 (0.54) | KCNN4KCNA3L3MBTL1CYP11B1CYP11B2 | |
| SCHEMBL9182074 | 0.79 | KCNN4 (0.57) | KCNN4KCNA3NR1I2ADORA3TBXA2R | |
| SCHEMBL2392101 | 0.77 | KCNN4 (0.72) | KCNN4KCNA3NR1I2ADORA3TBXA2R | |
| SCHEMBL9181765 | 0.75 | KCNN4 (0.50) | KCNN4KCNA3L3MBTL1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | claimed |
| WO-2017070536-A1 | METHODS AND AGENTS FOR TREATING DISEASES | ANGION BIOMEDICA CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | disclosed |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-12-20 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048270-A1 | Compounds, Methods And Devices for Inhibiting Neoproliferative Changes in Blood Vessel Walls | PGF, VEGFA, MKI67 | KCNN4 4235/4885KCNA3 4627/4885NR1I2 4061/4885 |
| US-20070293554-A1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | NFATC1, ORAI1, KCNMA1 | KCNN4 10/4885KCNA3 46/4885NR1I2 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.